Merck

Merck
Share

Merck

 •  July 27

Collaboration Aims to Maximize the Potential of PARP and MEK Inhibitors in Combination with PD-L1/PD-1 Medicines, Based on Growing Scientific Evidence That These Combinations Offer New Potential for the Treatment of a Range of Tumor Types
AstraZeneca and Merck Will Independently Develop and Commercialize LYNPARZA and Potential Medicine Selumetinib...

Merck

 •  July 25

Merck Plans to Submit New Drug Applications with the U.S. FDA in Q4 2017
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from the DRIVE-AHEAD study, the second of two pivotal Phase 3 clinical trials evaluating the efficacy and safety of doravirine, the company’s investigational,...

Merck

 •  July 24

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the U.S. launch of RENFLEXIS™ (infliximab-abda), a biosimilar of the originator biologic medicine Remicade (infliximab). RENFLEXIS was approved by the U.S. Food and Drug Administration (FDA) on April 21 for all eligible indications. RENFLEXIS is the first medicine...

Merck

 •  July 24

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the pivotal phase 3 KEYNOTE-040 trial investigating KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in previously treated patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) did not meet its pre-specified primary...

Merck

 •  July 24

Once-Daily Version of Raltegravir Now Approved in U.S. and European Union
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of Week 96 results from the pivotal Phase 3 ONCEMRK study evaluating the efficacy and safety of ISENTRESS HD1, a 1200 mg once-daily dose of the company’s integrase inhibitor,...

Merck

 •  July 20

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted tentative approval for LUSDUNA™ Nexvue™ (insulin glargine injection) 100 units/mL, a follow-on biologic1 basal insulin in a pre-filled dosing device. LUSDUNA Nexvue is being developed by Merck with...

Merck

 •  July 6

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new data from the company’s HIV portfolio and pipeline are scheduled to be presented at the 9th IAS Conference on HIV Science (IAS 2017). Presentations include late-breaker abstracts from two Phase 3 pivotal clinical trials – Week 96 data from ONCEMRK, a study...

Merck

 •  June 22

Call for health systems to join initiatives to improve care for specific patient populations
Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Premier Inc. (NASDAQ: PINC), a leading health care improvement company, have expanded their efforts to co-develop and test solutions to help improve patient care and wellness while...

Merck

 •  June 12

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today provided an update on two combination studies of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in the blood cancer multiple myeloma. Merck has accepted the external Data Monitoring Committee recommendation to pause new enrollment on KEYNOTE-183 and KEYNOTE-185,...

Merck

 •  June 5

Longer-Term Findings to Be Presented at 2017 ASCO Annual Meeting
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced updated overall survival (OS) findings from KEYNOTE-024, the phase 3 study evaluating KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, as a monotherapy compared to platinum-containing...